CIC
TOVX icon

Carnegie Investment Counsel’s Theriva Biologics TOVX Stock Holding History

Carnegie Investment Counsel’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-34
Closed -$756K – 303
2015
Q1 		$756K Buy
+34
New +$607K 0.13% 157

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Carnegie Investment Counsel's TOVX Position: Q2 2015 in Review

Carnegie Investment Counsel sold out of Theriva Biologics (TOVX) in Q2 2015, closing a stake of 34 shares — an estimated $756K sold.

Carnegie Investment Counsel first reported a position in TOVX in Q1 2015 and held it in 1 quarter. The position peaked at $756K in Q1 2015. 39 funds tracked by Wall St. Rank hold TOVX as of Q2 2015.

  • Carnegie Investment Counsel reported no remaining Theriva Biologics position as of Q2 2015 after selling out during the quarter.
  • Carnegie Investment Counsel sold 34 Theriva Biologics shares in Q2 2015, an estimated $756K.
  • Carnegie Investment Counsel first reported a position in Theriva Biologics in Q1 2015 and held it in 1 quarter.
  • Carnegie Investment Counsel's Theriva Biologics position peaked at $756K in Q1 2015.
  • 39 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2015.

Based on Carnegie Investment Counsel's 13F filing for Q2 2015, filed 13 Aug 2015.